King Pharma says petition for rehearing on Altace ruling denied

Dec 3 (Reuters) - King Pharmaceuticals Inc (KG.N) said the U.S. federal appeals court denied its petition for rehearing on a ruling that the patent on its biggest product, high blood pressure medicine Altace, was invalid.

The ruling would allow the sale of cheaper generic versions of the medicine known chemically as ramipril. (Reporting by Aniruddha Basu in Bangalore; Editing by Vinu Pilakkott)